Drug discovery is a long and challenging process, and making the right choices early on can save time, effort, and resources. At Pelago Bioscience, we provide services that help researchers confidently identify, validate, and refine drug candidates. Using Pelago Bioscience’s CETSA® technology, we generate biologically relevant data that expedites your drug discovery projects.
Here’s how Pelago Bioscience can support your drug discovery journey from beginning to end:
Target Discovery: Building a Strong Foundation
Choosing the right target is a crucial first step in drug development. We assist you in identifying and validating disease-relevant targets using CETSA in physiologically relevant models. A well-chosen target reduces risk, improves effectiveness, and increases the chances of success.
Target Identification - Our proteome-wide CETSA profiling provides a detailed picture of both on- and off-target interactions, helping you understand how your drug candidate affects cellular pathways and reducing the likelihood of unexpected side effects.
Assay Development - CETSA assays do not require protein modifications, making them quicker and easier to set up than traditional methods. We develop both standard and customized assays to meet your project's needs.
Tool Evaluation - We rigorously evaluate reference compounds to confirm their relevance and reliability so you can move forward confidently.
Lead Generation: Finding the Right Compounds
Our CETSA technology allows us to focus on molecules with the best chance of becoming successful drugs, improving efficiency and reducing wasted effort within your project.
Primary Screening & Hit Confirmation - Our structured screening campaigns include assay development, pilot screens, and confirmation tests to help refine your selection and eliminate false positives.
Functional Assays - A drug should do more than bind to a target—it should also produce the right effect. We offer CETSA and biochemical assays that help determine whether a drug candidate produces a meaningful biological response, making it easier to move forward with confidence.
Selectivity Profiling - Our unbiased proteome-wide profiling helps you assess both on- and off-target interactions, improving drug safety and effectiveness.
Lead Optimization: Refining Drug Candidates for Better Results
Once promising compounds are identified, they must be refined for safety, effectiveness, and overall drug suitability. We provide insights into potency ranking, mechanism of action, and translational studies to help you select the best candidates for further development.
Mechanism of Action - Knowing how a drug interacts with its target is key to improving its design. CETSA profiling helps researchers study the mechanism of action in biologically relevant conditions, ensuring that drug candidates work as expected.
Translational Studies - One challenge in drug development is ensuring preclinical findings hold up in clinical settings. CETSA allows smooth transitions from cell studies to more complex matrices such as tissues or whole blood, helping researchers confirm target engagement in real biological environments.
Preclinical Studies - Providing the Best Foundation for Clinical Trials
Researchers must determine safe starting doses and assess potential toxicity before a drug enters clinical trials. CETSA measures target engagement in preclinical models, helping inform clinical trial design with reliable and relevant data.
In Vivo Target Engagement - CETSA directly assesses target engagement in disease-relevant tissues, helping you predict a drug’s effectiveness and appropriate dosage before it enters human trials.
Biomarker Discovery - Biomarkers help researchers track drug effects and predict patient responses. Our CETSA-based profiling helps identify biomarkers that improve treatment strategies and support personalized medicine.
Why Work with Pelago Bioscience?
At Pelago Bioscience, we work closely with your teams to provide tailored solutions that support drug discovery. Our CETSA technology generates biologically relevant data that helps guide decision-making, reduce uncertainty, and move projects forward with greater confidence.
Interested in learning more? Contact us today to discuss how we can support your drug discovery efforts.
About Drug Discovery Innovation Programme 2025
The Drug Discovery Innovation Programme is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2025 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.